{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-005946","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.580974+00:00","generated_at":"2026-05-23T07:24:34.073971+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Kairos Pharma CEO letter updates ENV105 trials, DoD grant, and analyst coverage","bullets":["ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer trials; interim efficacy data expected end of Q2 2025.","CSO lab received $876k DoD grant for biomarker study; trial sites expanded to University of Utah and City of Hope.","Developing KROS101 GITR ligand agonist; data presented at AACR, SITC, and upcoming ASCO.","Non-dilutive government grants received; robust IP portfolio; analyst coverage from EF Hutton, Maxim, HC Wainwright, and others.","Financially strong due to recent private placement and non-dilutive funding; attending D. Boral and HC Wainwright conferences."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-005946","json":"https://secwatch.observer/filing/0001641172-25-005946.json","markdown":"https://secwatch.observer/filing/0001641172-25-005946.md","text":"https://secwatch.observer/filing/0001641172-25-005946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/0001641172-25-005946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:24:34.073971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}